Alemtuzumab: effective monotherapy for simultaneous B-cell chronic lymphocytic leukaemia and Sézary syndrome

Eur J Haematol. 2004 Dec;73(6):447-9. doi: 10.1111/j.1600-0609.2004.00332.x.

Abstract

The simultaneous presentation of chronic lymphocytic leukaemia (CLL) and cutaneous T-cell lymphoma (CTCL) is a very rare occurrence where optimal treatment is unknown. We present the case of a 65-yr-old man who was successfully treated with alemtuzumab monotherapy for both disorders, but at a cost of severe infectious morbidity and prolonged pancytopenia.

Publication types

  • Case Reports

MeSH terms

  • Absidia
  • Aged
  • Alemtuzumab
  • Anti-Infective Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm / therapeutic use*
  • Aspergillosis / drug therapy
  • Aspergillosis / etiology
  • Cellulitis / etiology
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / etiology
  • Humans
  • Immunization, Passive* / adverse effects
  • Immunocompromised Host
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Male
  • Mucormycosis / drug therapy
  • Mucormycosis / etiology
  • Neoplasms, Multiple Primary / therapy*
  • Pancytopenia / etiology
  • Remission Induction
  • Sezary Syndrome / therapy*
  • Sinusitis / etiology

Substances

  • Anti-Infective Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Neoplasm
  • Alemtuzumab